Search
Close this search box.

Freenome in artificial intelligence: theme innovation strategy

Freenome grant share with artificial intelligence as a theme is 0% in Q3 2023. Grant share is based on the ratio of number of grants to total number of patents.

Recent Patents

Application: Markers for the early detection of colon cell proliferative disorders (Patent ID: US20230243830A1)

Freenome Inc. has filed a patent for a method of detecting and treating colorectal cancer using a computer programmed with specific instructions. The method involves obtaining an autoantibody profile from a biological sample of the subject, which includes measuring the amount of autoantibodies from a predetermined panel of autoantibodies. The panel consists of autoantibodies to at least three antigens, such as NME5, USP16, UBE2S, RNF41, CD20, ANKHD1, TXNL1, NAT6, Supt6h, PRDM8, OTUD5, PNKP, SRSF7, ASB9, NXN, ZBTB21, EYA1, GSPT1, MLIP, RBM38, ARMC5, TP53, BRD9, CDK4, PRMT6, PCOLCE, and SDCBP. The autoantibody profile is then processed using a trained machine learning model to distinguish between subjects with colorectal cancer and those without. This provides an output value associated with the presence of colorectal cancer, allowing for the identification of the cancer in the subject. The method also includes detecting or treating the colorectal cancer based on the identification.

The patent claims also include variations of the method, such as using IgG autoantibodies, IgM autoantibodies, or a combination of both. The predetermined autoantibody panel can be configured to distinguish between healthy subjects, subjects with benign colon polyps, subjects with advanced adenoma, and subjects with colorectal cancer. The biological sample can be obtained from various sources, including body fluids, stool, urine, blood, tissue biopsy, and more. The colorectal cancer can encompass different types, such as adenoma, polyposis disorder, Lynch syndrome, colorectal dysplasia, colon cancer, rectal cancer, lymphoma, and sarcoma.

The patent also covers the use of the computer to determine the methylation status of nucleic acid molecules in the biological sample and to measure the amount of proteins in the sample. These additional data can be processed using the trained machine learning model to further enhance the detection and treatment of colorectal cancer.

In summary, Freenome Inc.’s patent describes a method of detecting and treating colorectal cancer using a computer programmed with specific instructions. The method involves obtaining an autoantibody profile from a biological sample, processing it using a trained machine learning model, and using the output value to identify and treat the cancer. The patent also covers variations of the method, including the use of different types of autoantibodies, sample sources, and additional data such as methylation status and protein levels.

To know more about GlobalData’s detailed insights on Freenome, buy the report here.

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.